August 25, 2014
Civitas Therapeutics Secures $55 Million in Series C Financing

August 20, 2014
California Cryobank (CCB) Announces Acquisition by Longitude Capital and NovaQuest Capital

July 24, 2014
Esperion Therapeutics Announces Initiation of a Phase 2 Clinical Study of ETC-1002 in Patients with Hypercholesterolemia and Hypertension

July 17, 2014
Practice Fusion Signs 122 Partnership Deals with Health System, Hospital, Lab and Imaging Clients in 2014

July 7, 2014
CardioDx Announces Aetna and Coventry Health Coverage for Corus® CAD Gene Expression Test

July 2, 2014
Jazz Pharmaceuticals Announces Agreement To Acquire Rights To Defibrotide In The Americas From Sigma-Tau Pharmaceuticals, Inc.

June 25, 2014
Practice Fusion and Emdeon Team Up to Simplify Medical Claim Filings on Practice Fusion’s Electronic Health Record (EHR) Platform

June 11, 2014
Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa®

June 4, 2014
Aptus Announces ANCHOR Registry Hits New Milestone of 400 Patients Enrolled

May 22, 2014
Venus Concept Secures $10 Million in Funding

May 21, 2014
Practice Fusion Launches Nation’s Largest Real-Time Healthcare Database

April 28, 2014
Practice Fusion Teams with Merck on Population Health Management Initiative

April 28, 2014
Civitas Therapeutics Announces Positive Phase 2b Results for CVT-301, Inhaled Levodopa for the Treatment of Parkinson's Disease

April 7, 2014
Practice Fusion Named the No. 1 Electronic Health Records (EHR) Vendor in Primary Care Practices for Fifth Year Running

April 2, 2014
Collegium Pharmaceutical Announces Positive Topline Results of Clinical Study Evaluating the Effect of Crushing Oxycodone DETERx® Compared with OxyContin®

April 2, 2014
US Oncology Research Joins Corcept Therapeutics' Phase I Breast Cancer Study

March 31, 2014
Jazz Pharmaceuticals And Gentium Announce European Commercial Launch Of First Approved Life-Saving Treatment For Severe Hepatic Veno-Occlusive Disease

March 31, 2014
Amarin and Kowa Pharmaceuticals America, Inc. Announce U.S. Co-Promotion Agreement for Vascepa(R) (icosapent ethyl) Capsules

March 19, 2014
Mallinckrodt plc Completes $1.4 Billion Acquisition of Cadence Pharmaceuticals, Inc.

March 18, 2014
Longitude Capital Maintains Momentum with Promotions and Team Expansion

March 10, 2014
Study Finds the Corus® CAD Gene Expression Blood Test Influenced Primary Care Decision- Making in the Assessment of Patients with Suspected Obstructive Coronary Artery Disease

February 27, 2014
Allergen Research Corporation Initiates Phase 2b Clinical Trial for Peanut Allergy Oral Immunotherapy

February 26, 2014
The Corus® CAD Gene Expression Test Can Help Commercial Health Plans Reduce Costs by Improving the Accuracy of the Diagnostic Workup in Patients with Suspected Obstructive Coronary Artery Disease

February 21, 2014
Amarin Announces FDA Award of Three-Year Exclusivity for Vascepa(R) (icosapent ethyl) Capsules

February 11, 2014
Jazz Pharmaceuticals Announces U.S. Commercial Availability Of Versacloz™ (clozapine, USP) Oral Suspension

February 11, 2014
Mallinckrodt plc to Acquire Cadence Pharmaceuticals, Inc. for $14.00 Per Share, in Cash

February 10, 2014
Jazz Pharmaceuticals Breaks Ground On New Manufacturing And Development Facility In Ireland

February 5, 2014
Report: Practice Fusion Nabs Top Spot as the Largest Cloud-Based EHR in the U.S.

February 4, 2014
Collegium Pharmaceutical Announces Completion of Enrollment in Pivotal Phase 3 Clinical Study for Oxycodone DETERx®,its Lead Abuse-Deterrent Development Program

February 3, 2014
The Corus® CAD Gene Expression Test Significantly Correlates With Plaque Burden and Obstructive Coronary Artery Disease as Validated by CT-Angiography

February 3, 2014
Valeant Pharmaceuticals to Acquire Precision Dermatology for $475 Million

January 15, 2014
Collegium Pharmaceutical Announces Positive Topline Results of Human Abuse Potential Study Evaluating Intranasal Administration of Crushed Oxycodone DETERx®, an Abuse-Deterrent, Extended-Release Product

January 15, 2014
Practice Fusion Receives ONC-ACB Certification from the Drummond Group

Januray 13, 2014
Practice Fusion Partners with Healthagen’s Practice iQ to Help Physician Groups Perform as ACOs

January 13, 2014
Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness

© 2008 Longitude Capital Management Co., LLC. All rights reserved.